A Phase 3, Multicenter, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of Navenibart in participants with Hereditary Angioedema (NCT06842823)
Alpha Orbit - STAR0215-301
This trial is No longer recruiting
Registration number NCT06842823
Navenibart is being developed as a prophylactic treatment for the prevention of Hereditary Angioedema attacks.
Program & service
This trial is being run with the Heart & Lung service, and as part of the Respiratory program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
A/Prof Celia Zubrinich
Key inclusion data
Documented diagnosis of HAE Type 1 or Type 2. Lab findings consistent with HAE Type 1 or 2. Documented clinical history consistent with HAE.
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR